VKTX: the balance sheet

MyFinsight

For the quarter ending 2026-03-31, VKTX has $608,242K in assets. $106,325K in debts. $118,116K in cash and cash equivalents.

Balance Sheets	2026-03-31	2025-12-31	2025-09-30	2025-06-30
Cash and cash equivalents	118,116	165,810	100,376	33,880
Short-term investments available for sale	484,848	539,929	614,194	773,844
Prepaid clinical trial and preclinical study costs	4,021	8,053	21,891	16,478
Prepaid expenses and other current assets	1,224	1,806	2,242	2,815
Total current assets	608,209	715,598	738,703	827,017
Right-of-use assets	0	85	666	780
Deferred financing costs	-	0	0	8
Deposits	33	46	46	46
Total assets	608,242	715,729	739,415	827,851

Accounts payable	67,183	53,251	4,413	5,494
Other accrued liabilities	39,142	23,279	21,217	26,018
Lease liability, current	0	137	437	468
Total current liabilities	106,325	76,667	26,067	31,980
Lease liability, net of current portion	-	0	318	410
Total long-term liabilities	-	0	318	410
Total liabilities	106,325	76,667	26,385	32,390
Common stock, 0.00001 par value 300,000,000 shares authorized at march 31, 2026 and december 31, 2025 115,893,943 shares issued and outstanding at march 31, 2026 and 114,793,067 shares issued and outstanding at december 31, 2025	1	1	1	1
Treasury stock at cost, no shares at december 31, 2025 and december 31, 2024	-	0	0	0
Additional paid-in capital	1,508,643	1,486,229	1,402,539	1,394,723
Accumulated deficit	-1,005,871	-847,546	-689,884	-599,097
Accumulated other comprehensive loss	-856	378	374	-166
Total stockholders equity	501,917	639,062	713,030	795,461
Total liabilities and stockholders equity	608,242	715,729	739,415	827,851

Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.